Artal Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Artal Group’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400,000	Closed	-$1.95M	–	142
2022 Q4	$1.95M	Hold	400,000	–	–	0.11%	89
2022 Q3	$5.77M	Hold	400,000	–	–	0.25%	55
2022 Q2	$6.05M	Hold	400,000	–	–	0.32%	49
2022 Q1	$4.75M	Hold	400,000	–	–	0.2%	82
2021 Q4	$6.48M	Hold	400,000	–	–	0.18%	88
2021 Q3	$11.4M	Hold	400,000	–	–	0.26%	75
2021 Q2	$13.5M	Hold	400,000	–	–	0.27%	77
2021 Q1	$12.1M	Buy	400,000 +114,972	+40%	+$4.71M	0.21%	91
2020 Q4	$14.1M	Hold	285,028	–	–	0.3%	76
2020 Q3	$10.9M	Sell	285,028 -15,002	-5%	-$597K	0.27%	75
2020 Q2	$13M	Sell	300,030 -99,970	-25%	-$3.78M	0.36%	60
2020 Q1	$10.4M	Hold	400,000	–	–	0.44%	46
2019 Q4	$12.5M	Hold	400,000	–	–	0.48%	38
2019 Q3	$10.4M	Hold	400,000	–	–	0.42%	45
2019 Q2	$9.15M	Buy	+400,000	New	+$9.19M	0.37%	55
2019 Q1	–	Sell	-50,000	Closed	-$1.02M	–	116
2018 Q4	$1.02M	Sell	50,000 -100,000	-67%	-$2.3M	0.04%	102
2018 Q3	$3.98M	Buy	+150,000	New	+$3.81M	0.1%	83

Other funds holding YMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Artal Group's YMAB Position: Q1 2023 in Review

Artal Group sold out of Y-mAbs Therapeutics (YMAB) in Q1 2023, closing a stake of 400,000 shares — an estimated $1.95M sold.

Artal Group first reported a position in YMAB in Q3 2018 and held it in 17 quarters. The position peaked at $14.1M in Q4 2020. 85 funds tracked by Wall St. Rank hold YMAB as of Q1 2023.

Artal Group reported no remaining Y-mAbs Therapeutics position as of Q1 2023 after selling out during the quarter.
Artal Group sold 400,000 Y-mAbs Therapeutics shares in Q1 2023, an estimated $1.95M.
Artal Group first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 17 quarters.
Artal Group's Y-mAbs Therapeutics position peaked at $14.1M in Q4 2020.
85 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.